XML 45 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
License and Collaboration Agreements - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Feb. 13, 2018
Jul. 23, 2017
Apr. 30, 2018
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Accounts receivable       $ 11,532,000   $ 11,532,000   $ 22,492,000  
Revenue, excluding assessed tax       23,625,000 $ 24,921,000 70,032,000 $ 76,898,000    
Bristol Myers Squibb Collaboration Agreement                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Accounts receivable       8,000,000   8,000,000   $ 21,400,000  
Bristol Myers Squibb Company | Purchase Agreement                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Shares issued (in shares)     8,284,600            
Sale of stock consideration received     $ 850,000,000            
Other Partner                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Potential future additional payments for development milestones (up to)       40,000,000   40,000,000      
Nektar-358 | Nektar's                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Received upfront and milestone payment   $ 150,000,000              
Percentage of sharing in Phase 2 development costs   25.00%              
Nektar-358 | Eli Lilly And Company | Maximum                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Potential future additional development and regulatory milestones (up to)   $ 250,000,000              
Nektar-358 | Eli Lilly And Company | Nektar's                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Percentage of regulatory milestones payments will be reduced under certain conditions   50.00%              
Percentage of regulatory milestones payments will be reduced if conditions occur   75.00%              
Nektar-358 | Eli Lilly And Company | Nektar's | Maximum                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Percentage of funding phase 3 development costs on an indication by indication basis borne   25.00%              
Nektar-358 | Eli Lilly                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Percentage of sharing in Phase 2 development costs   75.00%              
Nektar 214 | Bristol Myers Squibb Company                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Reimbursement of expenses       8,300,000   16,700,000      
Nektar 214 | Bristol Myers Squibb Company | Research and Development Expense                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Reimbursement of expenses         24,300,000 24,900,000 76,500,000    
Nektar 214 | Bristol Myers Squibb Collaboration Agreement | Nektar's                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Percentage of sharing production costs 65.00%                
Upfront and milestone payments received from license agreements     $ 1,000,000,000            
Nektar 214 | Bristol Myers Squibb Collaboration Agreement | Nektar's | Milestone One                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Potential future additional payments for development milestones (up to)                 $ 50,000,000
Nektar 214 | Bristol Myers Squibb Collaboration Agreement | Bristol Myers Squibb Company                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Percentage of sharing production costs 35.00%                
Nektar 214 | Opdivo | Bristol Myers Squibb Collaboration Agreement | Nektar's                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Percentage of sharing development costs 32.50%                
Nektar 214 | Opdivo | Bristol Myers Squibb Collaboration Agreement | Bristol Myers Squibb Company                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Percentage of sharing development costs 67.50%                
Non-cash royalty revenue related to the sales of future royalties                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue, excluding assessed tax       $ 18,342,000 $ 19,413,000 $ 52,167,000 $ 58,667,000